Clinical Trials
10 trialsNCT05681039 2026-06-02
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05394337 2026-05-05
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06760481 2026-04-15
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT06713798 2026-03-23
INDIGO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT06754501 2026-02-18
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04958811 2026-01-26
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Georgetown University
Phase 2 Active not recruiting
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT06784947 2025-10-02
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT03977467 2025-08-27
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
SCRI Development Innovations, LLC
Phase 2 Completed